000257518 001__ 257518
000257518 005__ 20231004134634.0
000257518 0247_ $$2doi$$a10.14283/jpad.2023.11
000257518 0247_ $$2pmid$$apmid:36946458
000257518 0247_ $$2pmc$$apmc:PMC9851094
000257518 0247_ $$2ISSN$$a2274-5807
000257518 0247_ $$2ISSN$$a2426-0266
000257518 0247_ $$2altmetric$$aaltmetric:144142110
000257518 037__ $$aDZNE-2023-00429
000257518 041__ $$aEnglish
000257518 082__ $$a610
000257518 1001_ $$0P:(DE-HGF)0$$aKönig, A.$$b0
000257518 245__ $$aScreening over Speech in Unselected Populations for Clinical Trials in AD (PROSPECT-AD): Study Design and Protocol.
000257518 260__ $$aCham$$bSpringer International Publishing$$c2023
000257518 3367_ $$2DRIVER$$aarticle
000257518 3367_ $$2DataCite$$aOutput Types/Journal article
000257518 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1690535572_3221
000257518 3367_ $$2BibTeX$$aARTICLE
000257518 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000257518 3367_ $$00$$2EndNote$$aJournal Article
000257518 520__ $$aSpeech impairments are an early feature of Alzheimer's disease (AD) and consequently, analysing speech performance is a promising new digital biomarker for AD screening. Future clinical AD trials on disease modifying drugs will require a shift to very early identification of individuals at risk of dementia. Hence, digital markers of language and speech may offer a method for screening of at-risk populations that are at the earliest stages of AD, eventually in combination with advanced machine learning. To this end, we developed a screening battery consisting of speech-based neurocognitive tests. The automated test performs a remote primary screening using a simple telephone.PROSPECT-AD aims to validate speech biomarkers for identification of individuals with early signs of AD and monitor their longitudinal course through access to well-phenotyped cohorts.PROSPECT-AD leverages ongoing cohorts such as EPAD (UK), DESCRIBE and DELCODE (Germany), and BioFINDER Primary Care (Sweden) and Beta-AARC (Spain) by adding a collection of speech data over the telephone to existing longitudinal follow-ups. Participants at risk of dementia are recruited from existing parent cohorts across Europe to form an AD 'probability-spectrum', i.e., individuals with a low risk to high risk of developing AD dementia. The characterization of cognition, biomarker and risk factor (genetic and environmental) status of each research participants over time combined with audio recordings of speech samples will provide a well-phenotyped population for comparing novel speech markers with current gold standard biomarkers and cognitive scores.N= 1000 participants aged 50 or older will be included in total, with a clinical dementia rating scale (CDR) score of 0 or 0.5. The study protocol is planned to run according to sites between 12 and 18 months.The speech protocol includes the following neurocognitive tests which will be administered remotely: Word List [Memory Function], Verbal Fluency [Executive Functions] and spontaneous free speech [Psychological and/ or behavioral symptoms]. Speech features on the linguistic and paralinguistic level will be extracted from the recordings and compared to data from CSF and blood biomarkers, neuroimaging, neuropsychological evaluations, genetic profiles, and family history. Primary candidate marker from speech will be a combination of most significant features in comparison to biomarkers as reference measure. Machine learning and computational techniques will be employed to identify the most significant speech biomarkers that could represent an early indicator of AD pathology. Furthermore, based on the analysis of speech performances, models will be trained to predict cognitive decline and disease progression across the AD continuum.The outcome of PROSPECT-AD may support AD drug development research as well as primary or tertiary prevention of dementia by providing a validated tool using a remote approach for identifying individuals at risk of dementia and monitoring individuals over time, either in a screening context or in clinical trials.
000257518 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000257518 588__ $$aDataset connected to DataCite
000257518 650_7 $$2Other$$aAlzheimer’s disease
000257518 650_7 $$2Other$$aDementia
000257518 650_7 $$2Other$$acognitive assessment
000257518 650_7 $$2Other$$amachine learning
000257518 650_7 $$2Other$$aphone-based
000257518 650_7 $$2Other$$ascreening
000257518 650_7 $$2Other$$aspeech biomarker
000257518 650_7 $$2NLM Chemicals$$aBiomarkers
000257518 650_2 $$2MeSH$$aHumans
000257518 650_2 $$2MeSH$$aAlzheimer Disease: psychology
000257518 650_2 $$2MeSH$$aBiomarkers
000257518 650_2 $$2MeSH$$aCognitive Dysfunction: psychology
000257518 650_2 $$2MeSH$$aMemory
000257518 650_2 $$2MeSH$$aSpeech
000257518 693__ $$0EXP:(DE-2719)DELCODE-20140101$$5EXP:(DE-2719)DELCODE-20140101$$eLongitudinal Cognitive Impairment and Dementia Study$$x0
000257518 693__ $$0EXP:(DE-2719)Prospect-AD-20220101$$5EXP:(DE-2719)Prospect-AD-20220101$$ePopulation-based screening over speech for clinical trials in Alzheimer’s Disease$$x1
000257518 693__ $$0EXP:(DE-2719)DESCRIBE-20150101$$5EXP:(DE-2719)DESCRIBE-20150101$$eA DZNE Clinical Registry Study of Neurodegenerative Diseases$$x2
000257518 7001_ $$aLinz, N.$$b1
000257518 7001_ $$aBaykara, E.$$b2
000257518 7001_ $$aTröger, J.$$b3
000257518 7001_ $$aRitchie, C.$$b4
000257518 7001_ $$aSaunders, S.$$b5
000257518 7001_ $$0P:(DE-2719)2000026$$aTeipel, S.$$b6$$udzne
000257518 7001_ $$0P:(DE-2719)2811683$$aKöhler, S.$$b7$$udzne
000257518 7001_ $$aSánchez-Benavides, G.$$b8
000257518 7001_ $$aGrau-Rivera, O.$$b9
000257518 7001_ $$aGispert, J. D.$$b10
000257518 7001_ $$aPalmqvist, S.$$b11
000257518 7001_ $$aTideman, P.$$b12
000257518 7001_ $$aHansson, O.$$b13
000257518 773__ $$0PERI:(DE-600)2782183-3$$a10.14283/jpad.2023.11$$gVol. 10, no. 2$$n2$$p314-321$$tThe journal of prevention of Alzheimer's disease$$v10$$x2274-5807$$y2023
000257518 8564_ $$uhttps://pub.dzne.de/record/257518/files/DZNE-2023-00429_Restricted.pdf
000257518 8564_ $$uhttps://pub.dzne.de/record/257518/files/DZNE-2023-00429_Restricted.pdf?subformat=pdfa$$xpdfa
000257518 909CO $$ooai:pub.dzne.de:257518$$pVDB
000257518 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000257518 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811683$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000257518 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000257518 9141_ $$y2023
000257518 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-12$$wger
000257518 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-12$$wger
000257518 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-12
000257518 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-12
000257518 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000257518 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000257518 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000257518 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000257518 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-23
000257518 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJPAD-J PREV ALZHEIM : 2022$$d2023-08-23
000257518 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJPAD-J PREV ALZHEIM : 2022$$d2023-08-23
000257518 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x0
000257518 980__ $$ajournal
000257518 980__ $$aVDB
000257518 980__ $$aI:(DE-2719)1510100
000257518 980__ $$aUNRESTRICTED